Elevance Health, Inc. ( (ELV) ) has released its Q2 earnings. Here is a breakdown of the information Elevance Health, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Elevance Health, Inc. is a prominent player in the healthcare sector, offering a wide range of medical, pharmacy, behavioral, and home health services to over 109 million consumers. The company is dedicated to enhancing the health of humanity by connecting individuals to essential care and resources.
In the second quarter of 2025, Elevance Health reported a significant increase in operating revenue, reaching $49.4 billion, a 14.3% rise from the previous year. Despite this growth, the company experienced a decline in operating gain and adjusted operating gain, attributed to elevated medical costs in Medicaid and ACA health plans.
Key financial metrics revealed a diluted EPS of $7.72 and an adjusted diluted EPS of $8.84. The company revised its full-year adjusted diluted EPS guidance to approximately $30.00. Notably, Elevance Health returned $2.0 billion of capital to shareholders and maintained a robust cash flow, with operating cash flow reaching $3.1 billion year-to-date.
The Health Benefits segment saw a revenue increase driven by higher premium yields and Medicare Advantage membership growth, although it faced challenges with Medicaid membership attrition. Meanwhile, the Carelon segment reported a 36% revenue increase, fueled by acquisitions and growth in CarelonRx product revenue.
Looking ahead, Elevance Health remains focused on managing healthcare costs and investing in advanced technology and value-based care delivery. Despite the evolving external environment, the company is confident in achieving long-term growth, aiming for at least 12% average annual growth in adjusted diluted EPS over time.